Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

Cited In for PubMed (Select 20614424)


Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany - results of a database analysis from May 2010 to April 2012.

Ehlken B, Anastassopoulou A, Hain J, Schröder C, Wahle K.

BMC Public Health. 2015 Jun 21;15:578. doi: 10.1186/s12889-015-1885-0.


The use of systematic reviews and reporting guidelines to advance the implementation of the 3Rs.

Avey MT, Fenwick N, Griffin G.

J Am Assoc Lab Anim Sci. 2015 Mar;54(2):153-62.


Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, Wang W, Wang X, Yan K, Qi X, Zhang X, Xin W, Lu Z, Li X, Bian T, Gao Y, Tan W, Ruan L.

Clin Vaccine Immunol. 2015 Jun;22(6):618-30. doi: 10.1128/CVI.00091-15. Epub 2015 Apr 1.


Should influenza immunization be mandatory for all health care providers?

[No authors listed]

Can J Hosp Pharm. 2015 Jan-Feb;68(1):60-3. No abstract available.


Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndrome.

Hawken S, Kwong JC, Deeks SL, Crowcroft NS, McGeer AJ, Ducharme R, Campitelli MA, Coyle D, Wilson K.

Emerg Infect Dis. 2015 Feb;21(2):224-31. doi: 10.3201/eid2102.131879.


Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine.

Alicino C, Infante MT, Gandoglia I, Miolo N, Mancardi GL, Zappettini S, Capello E, Orsi A, Tamburini T, Grandis M.

Hum Vaccin Immunother. 2014;10(7):1969-73. doi: 10.4161/hv.28961.


Management of community-acquired pneumonia in older adults.

Simonetti AF, Viasus D, Garcia-Vidal C, Carratalà J.

Ther Adv Infect Dis. 2014 Feb;2(1):3-16. doi: 10.1177/2049936113518041. Review.


Socioeconomic impact of seasonal (epidemic) influenza and the role of over-the-counter medicines.

Klepser ME.

Drugs. 2014 Sep;74(13):1467-79. doi: 10.1007/s40265-014-0245-1. Review.


Costs and benefits of influenza vaccination: more evidence, same challenges.

Ciancio BC, Rezza G.

BMC Public Health. 2014 Aug 8;14:818. doi: 10.1186/1471-2458-14-818.


Annual public health and economic benefits of seasonal influenza vaccination: a European estimate.

Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI; Vaccines Europe influenza working group.

BMC Public Health. 2014 Aug 7;14:813. doi: 10.1186/1471-2458-14-813.


Health-related behaviors and effectiveness of trivalent inactivated versus live attenuated influenza vaccine in preventing influenza-like illness among young adults.

Woolpert T, Phillips CJ, Sevick C, Crum-Cianflone NF, Blair PJ, Faix D.

PLoS One. 2014 Jul 11;9(7):e102154. doi: 10.1371/journal.pone.0102154. eCollection 2014.


4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.

Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R.

BMC Infect Dis. 2014 Jul 3;14:365. doi: 10.1186/1471-2334-14-365.


The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model.

Van Bellinghen LA, Meier G, Van Vlaenderen I.

PLoS One. 2014 Jun 6;9(6):e98437. doi: 10.1371/journal.pone.0098437. eCollection 2014.


Effectiveness of the trivalent influenza vaccine.

Kolber MR, Lau D, Eurich D, Korownyk C.

Can Fam Physician. 2014 Jan;60(1):50. No abstract available.


Targeted vaccine selection in influenza vaccination.

Wutzler P, Hardt R, Knuf M, Wahle K.

Dtsch Arztebl Int. 2013 Nov 22;110(47):793-8. doi: 10.3238/arztebl.2013.0793. Review.


Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study.

Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ.

PLoS Med. 2013 Oct;10(10):e1001527. doi: 10.1371/journal.pmed.1001527. Epub 2013 Oct 8.


Enhancement of collective immunity in Tokyo metropolitan area by selective vaccination against an emerging influenza pandemic.

Saito MM, Imoto S, Yamaguchi R, Tsubokura M, Kami M, Nakada H, Sato H, Miyano S, Higuchi T.

PLoS One. 2013 Sep 18;8(9):e72866. doi: 10.1371/journal.pone.0072866. eCollection 2013.


Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk